These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30418122)

  • 21. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
    Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
    Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
    Mease PJ; McInnes IB; Kirkham B; Kavanaugh A; Rahman P; van der Heijde D; Landewé R; Nash P; Pricop L; Yuan J; Richards HB; Mpofu S;
    N Engl J Med; 2015 Oct; 373(14):1329-39. PubMed ID: 26422723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The key role of proinflammatory cytokines, matrix proteins, RANKL/OPG and Wnt/β-catenin in bone healing of hip arthroplasty patients.
    Cassuto J; Folestad A; Göthlin J; Malchau H; Kärrholm J
    Bone; 2018 Feb; 107():66-77. PubMed ID: 29129760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature.
    Abrouk M; Gandy J; Nakamura M; Lee K; Brodsky M; Singh R; Zhu H; Farahnik B; Bhutani T; Koo J
    Skin Therapy Lett; 2017 Jul; 22(4):1-6. PubMed ID: 28732152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes of serum sclerostin and Dickkopf-1 levels during the menstrual cycle. A pilot study.
    Liakou CG; Mastorakos G; Makris K; Fatouros IG; Avloniti A; Marketos H; Antoniou JD; Galanos A; Dontas I; Rizos D; Tournis S
    Endocrine; 2016 Nov; 54(2):543-551. PubMed ID: 27601021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secukinumab for the treatment of psoriatic arthritis.
    Baronaite Hansen R; Kavanaugh A
    Expert Rev Clin Immunol; 2016 Oct; 12(10):1027-36. PubMed ID: 27550397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutrophil function following treatment of psoriatic arthritis patients with secukinumab: altered cytokine signalling but no impairment of host defence.
    Cross AL; Hawkes J; Frankland H; Mediana A; Wright HL; Goodson NJ; Edwards SW; Moots RJ
    Rheumatology (Oxford); 2023 Sep; 62(9):3025-3034. PubMed ID: 36617171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of TNF Inhibitors on Parathyroid Hormone and Wnt Signaling Antagonists in Rheumatoid Arthritis.
    Adami G; Orsolini G; Adami S; Viapiana O; Idolazzi L; Gatti D; Rossini M
    Calcif Tissue Int; 2016 Oct; 99(4):360-4. PubMed ID: 27307275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating Wnt/β-catenin signalling inhibitors and uraemic vascular calcifications.
    Yang CY; Chang ZF; Chau YP; Chen A; Yang WC; Yang AH; Lee OK
    Nephrol Dial Transplant; 2015 Aug; 30(8):1356-63. PubMed ID: 25817223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus.
    Gaudio A; Privitera F; Pulvirenti I; Canzonieri E; Rapisarda R; Fiore CE
    Diab Vasc Dis Res; 2014 Jan; 11(1):48-52. PubMed ID: 24227537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Systematic Review and Meta-analysis of Efficacy and Safety of Novel Interleukin Inhibitors in the Management of Psoriatic Arthritis.
    Bilal J; Riaz IB; Kamal MU; Elyan M; Sudano D; Khan MA
    J Clin Rheumatol; 2018 Jan; 24(1):6-13. PubMed ID: 28926467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
    McInnes IB; Mease PJ; Ritchlin CT; Rahman P; Gottlieb AB; Kirkham B; Kajekar R; Delicha EM; Pricop L; Mpofu S
    Rheumatology (Oxford); 2017 Nov; 56(11):1993-2003. PubMed ID: 28968735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis.
    de Rooy DP; Yeremenko NG; Wilson AG; Knevel R; Lindqvist E; Saxne T; Krabben A; Leijsma MK; Daha NA; Tsonaka S; Zhernakova A; Houwing-Duistermaat JJ; Huizinga TW; Toes RE; Baeten DL; Brouwer E; van der Helm-van Mil AH
    Ann Rheum Dis; 2013 May; 72(5):769-75. PubMed ID: 23041840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.
    McInnes IB; Mease PJ; Schett G; Kirkham B; Strand V; Williams N; Fox T; Pricop L; Jugl SM; Gandhi KK;
    Arthritis Res Ther; 2018 Jun; 20(1):113. PubMed ID: 29880010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secukinumab for rheumatology: development and its potential place in therapy.
    Koenders MI; van den Berg WB
    Drug Des Devel Ther; 2016; 10():2069-80. PubMed ID: 27445458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.
    Anastasilakis AD; Polyzos SA; Avramidis A; Toulis KA; Papatheodorou A; Terpos E
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):752-7. PubMed ID: 19832854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secukinumab: A Review in Psoriatic Arthritis.
    Shirley M; Scott LJ
    Drugs; 2016 Jul; 76(11):1135-45. PubMed ID: 27299434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.
    Göbel A; Kuhlmann JD; Link T; Wimberger P; Browne AJ; Rauner M; Hofbauer LC; Rachner TD
    Breast Cancer Res Treat; 2017 Aug; 164(3):737-743. PubMed ID: 28526959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis.
    Gatti D; Viapiana O; Idolazzi L; Fracassi E; Ionescu C; Dartizio C; Troplini S; Kunnathully V; Adami S; Rossini M
    Bone; 2014 Oct; 67():189-92. PubMed ID: 25003812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.